Genocea Biosciences has initiated a Phase I study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae). GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action. GEN-004 contains three unique protein antigens, SP0148, SP1912, and SP2108, shown by Genocea’s proprietary antigen discovery platform, ATLAS, to be associated with protective TH17 T cell respons...